AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript

AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.

Original reporting
Published Aug 13, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RCELBullishMed
01

Why it matters

Traders can update models around 2026 revenue growth, gross margin trajectory, and cash burn, with a key milestone of cash-flow breakeven targeted for Q4 2026.

02

Market read

Raised full-year 2026 revenue guidance, improved gross margin, reduced operating expenses, and provided a cash-flow breakeven timing target.

03

What to watch

The guidance range is broad ($86M-$89M) and depends on reimbursement stabilization and adoption; any delay in Medicare/CPT transition or clinical publication timing could pressure sentiment.

Relevance 8/10Novelty 8/10Timing: earnings call transcript released Aug. 13, covering Q2 results and full-year 2026 guidance

Background

AVITA Medical’s Q2 2026 earnings call focuses on RECELL scaling, expansion of the product portfolio (Cohealyx, PermeaDerm), and reimbursement/CPT-code developments affecting adoption.

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

AVITA Medical reported Q2 revenue of $21.7M, raised 2026 guidance to $86M-$89M, and targeted cash-flow breakeven in Q4 2026.

Expected impact

Likely positive bias for the stock on earnings-day positioning, with follow-through dependent on whether RECELL growth and cash burn continue.

Evidence & confidence

The article provides multiple decision-relevant datapoints: full-year revenue guidance range, gross margin expansion, operating expense reduction, and a stated breakeven timing milestone.

Market effects

Supports the acute wound care and regenerative medicine theme by signaling scaling of RECELL and improving unit economics (gross margin up).

Highlights international RECELL momentum (26% sequential RECELL revenue growth) and UK clinical experience, which may influence regional adoption expectations.

CMS reimbursement-related commentary and proposed CPT code changes could affect broader reimbursement dynamics for similar wound-care technologies.

Counterpoint

Despite revenue growth, the company still reports a sizable net loss ($7.7M) and low cash balance ($11.1M), so execution risk remains until breakeven.

Key entities

  • AVITA Medical, Inc.

    Subject of the earnings call transcript; reported Q2 results, updated 2026 guidance, and discussed reimbursement and product adoption.

  • RECELL

    Autologous cell harvesting device; drove most revenue and margin expansion in Q2.

  • Cohealyx

    Collagen-based dermal matrix; management discussed clinical follow-up data timing and review activity.

  • PermeaDerm

    Biosynthetic wound matrix; reported strong sequential growth in Q2.

  • CMS

    Proposed nationally published physician RVUs for skin cell suspension autograft codes, supporting reimbursement transparency.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.